Feed aggregator

Tonix Anticipates Launch of Key Depression, Cocaine Intoxication Trials

Biospace news - Mon, 07/11/2022 - 02:00
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.

MacroGenics Shutters Phase II Cancer Study Following 7 Patient Deaths

Biospace news - Mon, 07/11/2022 - 02:00
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.

Imago’s Journey to Phase III a Blessing in Disguise for MPN Patients

Biospace news - Mon, 07/11/2022 - 02:00
Imago's early failed experiments investigating the potential of LSD1 in sickle cell disease and thalassemia have turned out to be fortuitous for patients with myeloproliferative neoplasms.

Myrtelle Presents Latest Positive Data in Canavan Treatment Space

Biospace news - Mon, 07/11/2022 - 02:00
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.

Roche Commits to IgAN Space with Another Asset from Long-time Partner Ionis

Biospace news - Mon, 07/11/2022 - 02:00
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.

Long COVID Evidence Begins to Mount, Suggesting Biomarkers and a "Triangle" Effect

Biospace news - Mon, 07/11/2022 - 02:00
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.

BLS Report Shows Steady Increase in Healthcare Employment & Wages

Biospace news - Mon, 07/11/2022 - 02:00
The latest Employment Situation report from the Bureau of Labor Statistics shows that employment for healthcare workers is slowly but surely returning to its pre-pandemic levels.

Clinical Catch-Up: Vertex, Ayala, Arrowhead, Dyne & More

Biospace news - Mon, 07/11/2022 - 02:00
Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies.

Here’s how the $100 Human Genome will Change Medicine

Biospace news - Mon, 07/11/2022 - 02:00
A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.

Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries

World Pharma News - Fri, 07/08/2022 - 10:00
Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.

The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries.

Two-Thirds of 2021 FDA-Approved Drugs Supported with Genetic Data

Biospace news - Fri, 07/08/2022 - 02:00
Last year, the FDA's Center for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of them, were supported with genomic data.

On Cusp of Merck Acquisition, Seagen Makes Waves in Colorectal Cancer

Biospace news - Fri, 07/08/2022 - 02:00
Seagen recently presented positive pivotal Phase II data from its trial of Tukysa (tucatinib) in combination with trastuzumab in HER2-positive metastatic colorectal cancer.

AbbVie Half Breaks Up with Alector on Alzheimer's

Biospace news - Fri, 07/08/2022 - 02:00
In a filing with the SEC, Abbvie's decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.

Dynacure Axes Investigational Study of CNM Treatment

Biospace news - Fri, 07/08/2022 - 02:00
Dynacure has ended its Unite-CNM Phase I/II trial on DYN101, an investigational therapy for the treatment of myotubular and centronuclear myopathies.

Rational's Experimental Herpes Vaccine Shows Preclinical Promise

Biospace news - Fri, 07/08/2022 - 02:00
Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine in animal studies.

Adverum Slashes Workforce By 38%, Hones In On Eye Disease Candidate

Biospace news - Fri, 07/08/2022 - 02:00
Adverum Biotechnologies is cutting 78 jobs after announcing it had successfully amended its Investigational New Drug application for ADVM-022.to treat wet age-related macular degeneration.

Millions of COVID-19 Shots Discarded, while Intermittent Fasting Could Curb Serious Disease

Biospace news - Fri, 07/08/2022 - 02:00
With COVID-19 vaccination rates dropping, millions of doses are going to waste. Meanwhile, outdoors isn't sure-fire protection but long-term intermittent fasters may be spared severe disease.

Movers & Shakers: Adagio, Harpoon, Aravive, Nitrase and More

Biospace news - Fri, 07/08/2022 - 02:00
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.

Research Roundup: a Potential Vaccine for ALS & More

Biospace news - Fri, 07/08/2022 - 02:00
Researchers and biotech companies are working on developing vaccines and therapies for cancer, ALS, COVID-19, obesity and psoriasis. Here's a look at just some of them.

Working Moms: Redefining Success & Finding Balance in the Life Sciences

Biospace news - Fri, 07/08/2022 - 02:00
With one in three employed women in the U.S. also raising children at home, and the majority of U.S. moms working at least part-time, moms are working overtime to keep up with their male counterparts.